Anacetrapib

Generic Name: Anacetrapib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₂₅F_₁₀NO_₃

CAS Number: 875446-37-0

Unique Ingredient Identifier: P7T269PR6S

Indication: 用于冠状动脉疾病（CHD）和动脉粥样硬化。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Effect of Anacetrapib on Vascular Function and Arterial Stiffness

Completed

Conditions: Atherosclerotic Cardiovascular Disease
Vascular Disease

Interventions: Drug: Statin
Drug: Anacetrapib
Drug: Placebo

First Posted Date: 2016-10-12

Last Posted Date: 2024-02-07

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 103

Registration Number: NCT02931188

Locations: 🇬🇧
Clinical Investigation Ward, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Anacetrapib
Drug: Placebo

First Posted Date: 2013-05-23

Last Posted Date: 2020-05-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 589

Registration Number: NCT01860729

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

Phase 3

Terminated

Conditions: Homozygous Familial Hypercholesterolemia
Hyperlipoproteinemia Type II

Interventions: Drug: Placebo
Drug: Anacetrapib

First Posted Date: 2013-04-26

Last Posted Date: 2015-06-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 2

Registration Number: NCT01841684

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Phase 3

Completed

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH)

Interventions: Drug: Placebo for anacetrapib
Drug: Anacetrapib

First Posted Date: 2013-04-04

Last Posted Date: 2016-04-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 68

Registration Number: NCT01824238

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Phase 3

Completed

Conditions: Dyslipidemia

Interventions: Drug: Placebo for anacetrapib
Drug: Anacetrapib

First Posted Date: 2013-01-04

Last Posted Date: 2017-06-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 307

Registration Number: NCT01760460

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Phase 3

Completed

Conditions: Hyperlipoproteinemia Type II
Hypercholesterolemia, Familial

Interventions: Drug: Placebo
Drug: Anacetrapib

First Posted Date: 2012-02-01

Last Posted Date: 2019-10-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 306

Registration Number: NCT01524289

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Phase 3

Active, not recruiting

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Anacetrapib
Drug: Placebo anacetrapib

First Posted Date: 2010-12-03

Last Posted Date: 2024-06-25

Lead Sponsor: University of Oxford

Target Recruit Count: 30449

Registration Number: NCT01252953

Locations: 🇬🇧
CTSU, University of Oxford, Oxford, Oxfordshire, United Kingdom

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: anacetrapib

First Posted Date: 2010-05-13

Last Posted Date: 2015-08-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT01122667

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: anacetrapib

First Posted Date: 2010-05-03

Last Posted Date: 2015-10-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT01114490

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: anacetrapib

First Posted Date: 2009-10-07

Last Posted Date: 2015-06-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 46

Registration Number: NCT00990808

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy